Home
Resources
Publications
The Role of Microsomal Triglyceride Transfer Protein Inhibitors in the Treatment of Patients With Familial Hypercholesterolemia: Risks, Benefits, and Management

The Role of Microsomal Triglyceride Transfer Protein Inhibitors in the Treatment of Patients With Familial Hypercholesterolemia: Risks, Benefits, and Management

Zahid Ahmad, Amit Khera

Curr Atheroscler Rep. 2015 Jan;17(1):469.

PMID: 25408543

Abstract:

Statins fail to adequately reduce low-density lipoprotein-cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia, requiring these patients to undergo weekly or bi-weekly sessions of LDL apheresis. Although efficacious, LDL apheresis is an invasive procedure with high cost and low availability, and additional options, such as inhibitors of microsomal transfer protein (MTP), may have benefit. Inhibition of MTP reduces levels of circulating cholesterol and triglycerides by preventing the formation of very-low-density lipoprotein and chylomicrons. LDL-C levels decrease by as much as 50%. Unfortunately, adverse effects-the most common of which are gastrointestinal-related and hepatic lipid accumulation-limit broader use of the drug. Furthermore, the cardiovascular benefit of MTP inhibition remains unclear. However, MTP inhibition offers a viable additional lipid-lowering option for patients with homozygous familial hypercholesterolemia.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
IAR42414846	Human Microsomal Transfer Protein (MTP)			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: